^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Lymphoma
    Drug:Rituxan (rituximab) (CD20 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    PRIMARY CNS LYMPHOMA: Preferred Regimens...High-dose methotrexate….combined with…Rituximab and TMZ...Other Recommended Regimens...Lenalidomide with or without rituximab... PRIMARY CNS LYMPHOMA….Useful in Certain Circumstances...Consider high-dose systemic therapy with autologous stem cell reinfusion in eligible patients...High-dose cytarabine + rituximab + thiotepa followed by thiotepa + rituximab + carmustine
    Secondary therapy:
    cytarabine + thiotepa; TT-BCNU; lenalidomide; temozolomide + methotrexate
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    PRIMARY CNS LYMPHOMA : Preferred Regimen... Rituximab...Other Recommended Regimens...Lenalidomide with or without rituximab...
    Secondary therapy:
    lenalidomide; temozolomide